Core Viewpoint - The transition of fund managers to the role of company secretaries in listed companies is becoming more common, reflecting the evolving relationship between fund companies and listed firms [1][3]. Group 1: Transition of Fund Managers - The recent appointment of a former fund manager as a company secretary highlights a shift in career paths, which is often perceived as a downgrade from the prestigious role of a fund manager [1][3]. - The movement of fund managers to listed companies is expected to increase as the fund industry develops, due to the natural business connections and resource sharing between the two sectors [3][4]. Group 2: Motivations for Transition - Many fund managers face significant investment pressures, particularly those with average or poor investment skills, leading them to seek less stressful job opportunities [3][4]. - Long-term fund managers may experience adverse effects on their mental and physical health due to the continuous pressure of their roles, making a transition to less demanding positions a reasonable choice [4]. Group 3: Benefits of the Transition - Fund managers transitioning to company secretaries can strengthen the relationship between listed companies and fund firms, leveraging their market knowledge and connections to enhance company performance [4]. - The expertise of fund managers in understanding market demands, especially from institutional investors, positions them well to contribute positively to the strategic direction of the companies they join [4].

Core Viewpoint - The appointment of Jiang Ying as the new Secretary of the Board at Luoxin Pharmaceutical is a significant development, although her lack of experience in listed company secretary roles raises questions about her suitability for the position [3][6]. Company Overview - Luoxin Pharmaceutical, founded in 1988, has a diverse product range covering various medical fields including gastrointestinal diseases, pediatrics, oncology, and more [6]. - The company has experienced significant performance fluctuations in recent years, primarily due to the impacts of the COVID-19 pandemic, impairment provisions, and adjustments in financial liabilities [6]. Financial Performance - For the first half of 2025, Luoxin Pharmaceutical reported a revenue of 1.077 billion, a decrease of 14.45% year-on-year, while achieving a net profit attributable to shareholders of 17.695 million, marking a turnaround from losses in the previous year [6][7]. - The total revenue for the latest reporting period was 1.077 billion, with a total cost of 1.098 billion, resulting in an operating profit of 39.41 million, which is a 133.12% increase year-on-year [7]. - The net profit attributable to the parent company's shareholders was 17.695 million, reflecting a 119.95% increase compared to the same period last year [7]. Management Background - Jiang Ying, the newly appointed Secretary of the Board, has a strong academic background with dual degrees in Science and Economics from Peking University, as well as a Master's in Management from Peking University and a Master's in Finance from the University of Hong Kong [3][5]. - Prior to her appointment, Jiang Ying worked in various roles at Guotai Junan Securities, Everbright Pramerica Fund, and Guotai Fund, but lacks experience in listed company secretary positions [3][5].